| Previous Close | 143.64 |
| Open | 143.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 141.82 - 144.46 |
| 52 Week Range | 96.18 - 149.34 |
| Volume | 1,288,550 |
| Avg. Volume | 1,862,184 |
| Market Cap | 31.88B |
| Beta | 1.31 |
| PE Ratio (TTM) | 61.94 |
| EPS (TTM) | 2.31 |
| Earnings Date | Oct 25, 2017 - Oct 30, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 163.45 |
- Zacks•16 hours ago
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.
- Zacks•16 hours ago
Pluristem's Ischemia Candidate Gets Fast Track Designation
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
- Zacks•18 hours ago
Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher
Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.
